Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18616995 | NEUROACTIVE STEROIDS AND THEIR METHODS OF USE | March 2024 | November 2024 | Allow | 7 | 1 | 0 | No | No |
| 18538065 | USE OF OUABAIN ANTAGONISTS TO INHIBIT VIRAL INFECTION | December 2023 | May 2025 | Abandon | 17 | 1 | 0 | No | No |
| 18494730 | 6-(4,5-BIS(4-BROMOPHENYL)-2-(4-METHOXYPHENYL)-1H-IMIDAZOL-1-YL)HEXANOIC ACID AS AN ANTIMICROBIAL COMPOUND | October 2023 | October 2024 | Abandon | 12 | 2 | 1 | No | No |
| 18482079 | NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF | October 2023 | May 2025 | Abandon | 19 | 1 | 0 | No | No |
| 18463293 | GLUCOCORTICOID RECEPTOR AGONISTS | September 2023 | March 2025 | Allow | 18 | 1 | 0 | No | No |
| 18455324 | CRYSTALLINE 19-NOR C3,3-DISUBSTITUTED C21-N-PYRAZOLYL STEROID | August 2023 | March 2025 | Allow | 18 | 1 | 0 | No | No |
| 18229105 | COMPOSITIONS AND METHODS OF USE FOR TREATING ABERRANT INFLAMMATION IN PERI-OCULAR SECRETORY GLANDS OR AT THE OCULAR SURFACE | August 2023 | March 2025 | Allow | 19 | 1 | 0 | No | No |
| 18057031 | ENZYMATIC PROCESS FOR OBTAINING 17 ALPHA-MONOESTERS OF CORTEXOLONE AND/OR ITS 9,11-DEHYDRODERIVATIVES | November 2022 | February 2025 | Allow | 27 | 1 | 0 | No | No |
| 17969105 | 3,3 DISUBSTITUTED 19-NOR PREGNANE COMPOUNDS, COMPOSITIONS, AND USES THEREOF | October 2022 | May 2025 | Abandon | 31 | 3 | 0 | No | No |
| 17940716 | EDIBLE CBD AND/OR THC PRODUCTS AND METHODS | September 2022 | June 2025 | Abandon | 33 | 1 | 0 | No | No |
| 17834798 | MEDICINAL COMPOUNDS AND NUTRITIONAL SUPPLEMENTS | June 2022 | May 2025 | Abandon | 35 | 1 | 1 | No | No |
| 17718520 | NUTRITIONAL COMPOSITION FOR GASTROINTESTINAL ENVIRONMENT TO PROVIDE IMPROVED MICROBIOME AND METABOLIC PROFILE | April 2022 | June 2025 | Abandon | 38 | 2 | 1 | No | No |
| 17640715 | PROCESS FOR PREPARING PYRIMIDINYL BIPYRIDINE COMPOUND AND INTERMEDIATE THEREFOR | March 2022 | March 2025 | Allow | 37 | 0 | 1 | No | No |
| 17580718 | SYSTEM AND METHOD FOR CANNABINOID OIL EMULSIFICATION | January 2022 | November 2023 | Abandon | 22 | 1 | 0 | No | No |
| 17626377 | PIPERIDINEDIONE DERIVATIVES | January 2022 | March 2025 | Allow | 38 | 0 | 1 | No | No |
| 17567704 | METHODS OF TESTOSTERONE THERAPY | January 2022 | May 2025 | Abandon | 40 | 2 | 0 | No | No |
| 17442925 | COMBINATION THERAPY OF ALK-POSITIVE NEOPLASIA | September 2021 | April 2025 | Abandon | 42 | 0 | 1 | No | No |
| 17442302 | SOLID STATE FORMS OF ACALABRUTINIB | September 2021 | February 2025 | Abandon | 41 | 0 | 1 | No | No |
| 17433273 | Imidazolopyridine Compounds For IRE1 Inhibition | August 2021 | February 2025 | Abandon | 42 | 0 | 1 | No | No |
| 17430180 | GRANZYME B DIRECTED IMAGING AND THERAPY | August 2021 | January 2025 | Abandon | 41 | 0 | 1 | No | No |
| 17426219 | BENZOPYRIDONE HETEROCYCLIC COMPOUND AND USE THEREOF | July 2021 | December 2024 | Abandon | 40 | 0 | 1 | No | No |
| 17423505 | CUBIC CYCLODEXTRIN FRAMEWORK-RGD COMPOSITION AND PREPARATION METHOD THEREFOR | July 2021 | December 2024 | Abandon | 41 | 0 | 1 | No | No |
| 17423527 | SALT OF EGFR INHIBITOR, CRYSTAL FORM, AND PREPARATION METHOD THEREFOR | July 2021 | March 2025 | Abandon | 44 | 0 | 1 | No | No |
| 17423143 | CRYSTALLINE FORM OF A CDK INHIBITOR | July 2021 | January 2025 | Abandon | 42 | 0 | 1 | No | No |
| 17422116 | COMPOSITION FOR ALLERGY PREVENTION, ATOPIC DERMATITIS ALLEVIATION OR SKIN REGENERATION, CONTAINING, AS ACTIVE INGREDIENT, UNDECANE OR UNDECANAL | July 2021 | March 2025 | Abandon | 44 | 1 | 0 | No | No |
| 17418406 | AZA-HETEROBICYCLIC INHIBITORS OF MAT2A AND METHODS OF USE FOR TREATING CANCER | June 2021 | October 2024 | Abandon | 40 | 0 | 1 | No | No |
| 17415684 | ORAL FORMULATIONS OF BRANAPLAM | June 2021 | January 2025 | Abandon | 43 | 1 | 0 | No | No |
| 17415335 | MACROCYCLIC COMPOUNDS AND THEIR USE IN THE TREATMENT OF DISEASE | June 2021 | December 2024 | Abandon | 42 | 0 | 1 | No | No |
| 17304216 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR PRODUCING LOW IMPURITY CONCENTRATIONS OF THE SAME | June 2021 | November 2024 | Abandon | 41 | 0 | 1 | No | No |
| 17413319 | COMBINATION OF FAK INHIBITOR AND BTK INHIBITOR FOR TREATING A DISEASE | June 2021 | October 2024 | Abandon | 41 | 1 | 0 | No | No |
| 17312776 | SUBSTITUTED PYRROLOPYRIDINE-DERIVATIVES | June 2021 | January 2025 | Abandon | 43 | 0 | 1 | No | No |
| 17294762 | Helicase Primase Inhibitors For Treating Cancer In A Combination Therapy With Oncolytic Viruses | May 2021 | January 2025 | Abandon | 44 | 1 | 1 | Yes | No |
| 17308501 | SELECTIVE ESTROGEN RECEPTOR DEGRADER | May 2021 | October 2024 | Abandon | 42 | 1 | 0 | No | No |
| 17244304 | COMPOSITION, SPRAY, AND WIPER | April 2021 | December 2024 | Abandon | 43 | 1 | 0 | No | No |
| 17232383 | Methods for Treating Cancer Using Pyrimidine and Pyridine Compounds with BTK Inhibitory Activity | April 2021 | January 2025 | Abandon | 45 | 2 | 0 | No | No |
| 15999066 | INDOLE DERIVATIVE AND ANTI-CANCER CONPOSITION CONTAINING SAME | April 2021 | June 2025 | Abandon | 60 | 3 | 0 | No | No |
| 17282618 | COMBINATIONS WITH A C-19 STEROID FOR TREATING CANCERS | April 2021 | February 2025 | Abandon | 46 | 1 | 1 | No | No |
| 17275748 | HSP90-TARGETING CONJUGATES AND FORMULATIONS THEREOF | March 2021 | December 2024 | Abandon | 45 | 0 | 1 | No | No |
| 17191281 | METHODS FOR ASSEMBLY OF TETRACYCLIC COMPOUNDS BY STEREOSELECTIVE C9-C10 BOND FORMATION | March 2021 | July 2022 | Allow | 16 | 1 | 1 | No | No |
| 17256777 | NEUROACTIVE STEROIDS AND METHODS OF PREPARATION | December 2020 | May 2022 | Allow | 17 | 1 | 0 | Yes | No |
| 17134929 | COMPOSITIONS AND METHODS FOR TREATING CNS DISORDERS | December 2020 | June 2025 | Abandon | 53 | 3 | 1 | No | No |
| 16980724 | A Biochip Substrate, Preparation Method and Application Thereof | September 2020 | September 2024 | Abandon | 48 | 1 | 1 | No | No |
| 16993834 | CRYSTALLINE FORMS OF QUINOLINE ANALOGS AND SALTS THEREOF, COMPOSITIONS, AND THEIR METHODS FOR USE | August 2020 | June 2023 | Abandon | 34 | 1 | 0 | No | No |
| 16961767 | ACTIVATION OF MITOCHONDRIAL UNCOUPLING AS A THERAPEUTIC INTERVENTION | July 2020 | November 2024 | Abandon | 52 | 1 | 1 | No | No |
| 16643776 | OPTIMAL OSMOTIC RANGE FOR A DRUG-CONTAINING SOLUTION SUITABLE FOR LYMPHATIC DELIVERY | March 2020 | June 2025 | Abandon | 60 | 6 | 1 | Yes | No |
| 16674209 | HERIPENES WITH PAIN-RELIEVING EFFECT, ACTIVE SUBSTANCES OF Hericium erinaceus MYCELIUM AND THE PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE HERIPENES OR ACTIVE SUBSTANCES | November 2019 | January 2023 | Allow | 38 | 2 | 1 | No | No |
| 16324265 | COMPOSITION FOR TREATING SKIN CONDITIONS | February 2019 | January 2023 | Allow | 47 | 3 | 1 | No | No |
| 15314565 | NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF | November 2016 | July 2020 | Abandon | 43 | 7 | 0 | Yes | Yes |
| 14414171 | Honey-based dressing for the treatment of wounds and burns | September 2015 | November 2017 | Abandon | 34 | 0 | 1 | No | No |
| 13322147 | METHOD FOR EXTRACTION OF FRACTIONS CONTAINING PHARMACOLOGICALLY ACTIVE INGREDIENTS WITH LESS CYTOTOXICITY FROM ONE OR MORE PLANTS | November 2011 | March 2014 | Allow | 28 | 2 | 1 | No | No |
| 13292395 | CHINESE MEDICINE COMPOSITION FOR TREATING CANCER | November 2011 | January 2013 | Allow | 15 | 1 | 0 | No | No |
| 13193029 | HAIR CARE SOLUTION FORMING A FILM PROTECTING NATURAL HAIR FROM GLUING PRODUCTS | July 2011 | June 2013 | Allow | 22 | 2 | 0 | Yes | No |
| 13157574 | COSMETIC USE OF AN ACTIVE AGENT CAPABLE OF STIMULATING TENSIN 1 EXPRESSION | June 2011 | February 2012 | Allow | 8 | 0 | 0 | No | No |
| 13062289 | NATURAL PRESERVATIVE ALTERNATIVES AND COMPOSITIONS CONTAINING SAME | April 2011 | September 2013 | Allow | 30 | 2 | 1 | No | No |
| 12739921 | STANDARDIZED PLANT EXTRACT, PROCESS FOR OBTAINING THE SAME AND USES THEREOF | August 2010 | November 2012 | Allow | 31 | 1 | 2 | No | No |
| 12820064 | NATURAL COMPOSITION FOR CURING HEPATITIS-B, METHODS FOR MAKING THE SAME AND PHARMACEUTICAL FORMULATIONS THEREOF | June 2010 | October 2011 | Allow | 16 | 1 | 1 | No | No |
| 12519137 | HERBAL FORMULATION FOR WOUND HEALING | March 2010 | January 2015 | Allow | 60 | 3 | 1 | No | No |
| 12568502 | CAFFEINE FRACTION OBTAINED FROM TEA LEAVES AND A METHOD FOR INDUCING AGROBACTERIUM TUMEFACIENS-MEDIATED GENETIC TRANSFORMATION IN PLANTS USING SAID CAFFEINE FRACTION | September 2009 | September 2010 | Allow | 12 | 1 | 0 | No | No |
| 12188566 | HERBAL COMPOSITION FOR TREATMENT OF HYPERLIPIDEMIA AND THE INHIBITION OF MYOCARDIAL INFARCTION | August 2008 | July 2011 | Allow | 35 | 1 | 1 | No | No |
| 12074863 | NUTRITIONAL COMPOSITION | March 2008 | February 2010 | Allow | 24 | 1 | 1 | No | No |
| 11979355 | METHODS OF TREATING EPIPHORA | November 2007 | December 2010 | Allow | 53 | 2 | 1 | Yes | No |
| 11899590 | COMPOSITION AND METHOD FOR TREATING AUTOIMMUNE DISEASE AND MUCOSAL DISORDER | September 2007 | December 2010 | Allow | 39 | 2 | 0 | No | Yes |
| 11819220 | HERBAL EXTRACTS OF SALICORNIA SPECIES, PROCESS OF PREPARATION THEREOF, USE THEREOF AGAINST TUBERCULOSIS | June 2007 | June 2008 | Allow | 12 | 1 | 0 | No | No |
| 11519310 | METHOD FOR OBTAINING TAXANES | September 2006 | December 2009 | Allow | 39 | 2 | 1 | Yes | No |
| 10809187 | INTERMITTENT IMMERSION VESSEL APPARATUS AND PROCESS FOR PLANT PROPAGATION | March 2004 | September 2005 | Allow | 18 | 0 | 2 | No | No |
| 10480078 | PHARMACEUTICAL FORMULATION CONSISTING OF A PLANT DRY EXTRACT WITH A CALCIUM COATING | December 2003 | July 2009 | Allow | 60 | 5 | 1 | Yes | No |
| 10648026 | ACUPOINT PATCH | August 2003 | September 2009 | Allow | 60 | 4 | 1 | No | No |
| 10396593 | CAFFEINE FRACTION OBTAINED FROM TEA LEAVES AND A METHOD FOR INDUCING AGROBACTERIUM TUMEFACIENS-MEDIATED GENETIC TRANSFORMATION IN PLANTS USING SAID CAFFEINE FRACTION | March 2003 | May 2008 | Abandon | 60 | 4 | 1 | No | No |
| 10387700 | METHOD FOR OBTAINING TAXANES | March 2003 | May 2006 | Allow | 38 | 1 | 0 | No | No |
| 10230352 | FOOD SUPPLEMENTS COMPRISING, AS A HEALTH COMPONENT, SARGAHYDROQUINOIC ACID OR DERIVATIVE THEREOF | August 2002 | April 2009 | Allow | 60 | 2 | 2 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner CLARK, AMY LYNN.
With a 0.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 33.3% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner CLARK, AMY LYNN works in Art Unit 1628 and has examined 69 patent applications in our dataset. With an allowance rate of 43.5%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 40 months.
Examiner CLARK, AMY LYNN's allowance rate of 43.5% places them in the 5% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by CLARK, AMY LYNN receive 1.36 office actions before reaching final disposition. This places the examiner in the 28% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by CLARK, AMY LYNN is 40 months. This places the examiner in the 7% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +26.7% benefit to allowance rate for applications examined by CLARK, AMY LYNN. This interview benefit is in the 77% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 12.1% of applications are subsequently allowed. This success rate is in the 3% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 46.2% of cases where such amendments are filed. This entry rate is in the 64% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 200.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 92% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.
This examiner withdraws rejections or reopens prosecution in 50.0% of appeals filed. This is in the 11% percentile among all examiners. Of these withdrawals, 100.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner rarely withdraws rejections during the appeal process compared to other examiners. If you file an appeal, be prepared to fully prosecute it to a PTAB decision. Per MPEP § 1207, the examiner will prepare an Examiner's Answer maintaining the rejections.
When applicants file petitions regarding this examiner's actions, 120.0% are granted (fully or in part). This grant rate is in the 98% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 8.7% of allowed cases (in the 95% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 1% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.